ストックスクリーナーアプリを入手
7.33
1.81%
0.13
プレマーケット:
7.30
-0.03
-0.41%
前日終値:
$7.20
開ける：
$6.74
24時間の取引高:
4.09M
Relative Volume:
1.39
時価総額：
$535.02M
収益：
$161.10M
当期純損益:
$-308.60M
株価収益率:
-1.5696
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
+12.60%
1か月 パフォーマンス:
-5.05%
6か月 パフォーマンス:
-71.50%
1年 パフォーマンス:
-77.88%
1日の値動き範囲:
$6.70
$7.44
1週間の範囲:
$6.48
$7.60
52週間の値動き範囲:
$5.90
$34.11
Arvinas Inc Stock (ARVN) Company Profile
ARVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.33 | 488.31M | 161.10M | -308.60M | -259.90M | -4.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-05 | ダウングレード | Truist | Buy → Hold |
| 2025-05-02 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-02 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-01 | 開始されました | Goldman | Buy |
| 2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 開始されました | Barclays | Overweight |
| 2022-06-21 | 開始されました | Jefferies | Hold |
| 2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2022-01-19 | 開始されました | Goldman | Buy |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-09 | 開始されました | BofA Securities | Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-21 | 開始されました | Truist | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Perform |
| 2019-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-25 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-25 | 開始されました | Wedbush | Outperform |
| 2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
| 2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-22 | 開始されました | Citigroup | Buy |
| 2018-10-22 | 開始されました | Goldman | Neutral |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
Arvinas (NASDAQ:ARVN) Cut to "Hold" at Leerink Partnrs - MarketBeat
What Analysts Are Saying About Arvinas Stock - Benzinga
Transcript : Arvinas, Inc.Special Call - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, ... - Bluefield Daily Telegraph
Arvinas (ARVN) Poised for Milestone with VERITAC-2 Trial Data | - GuruFocus
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant - The Pharma Letter
Arvinas (ARVN) Sees Downgrade from Leerink Partners | ARVN Stock News - GuruFocus
Arvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink Partners - MarketBeat
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell - marketscreener.com
Arvinas and Pfizer Announce Phase 3 Trial Results - TipRanks
Bank of America Corp DE Sells 350,298 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Leerink cuts Arvinas stock rating post ASCO meeting By Investing.com - Investing.com Nigeria
Arvinas (ARVN) Faces Downgrade Amid Clinical Trial Results | ARV - GuruFocus
Arvinas (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WTVB
Arvinas (NASDAQ:ARVN) Shares Down 4.7%What's Next? - MarketBeat
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
(ARVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Voloridge Investment Management LLC Invests $749,000 in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - Pfizer
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Is Trump Media Stock a Buy After $2.5 Billion Bitcoin Treasury Deal? - The Globe and Mail
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - MSN
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer - BioPharma Dive
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
3 Dividend Stocks to Buy With $500 and Hold Forever - The Globe and Mail
Arvinas (NASDAQ:ARVN) Trading Up 7.9%Still a Buy? - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference | ARVN Stock News - GuruFocus
Protein Degradation Pioneer Arvinas Reveals Latest Progress at Major Jefferies Healthcare Conference - Stock Titan
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - Yahoo Finance
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) - Business Wire
Analysts Are Saying TJX Companies Is a Buy Despite Lackluster Quarterly Earnings. Are They Right? - The Globe and Mail
Prediction: 2 AI Stocks Will Be Worth More Than Apple Stock Before the End of 2026 - The Globe and Mail
3 Top High-Yield Dividend Stocks to Buy and Hold Through at Least the End of the Decade - The Globe and Mail
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com South Africa
Woodline Partners LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks - Investing.com
Twinbeech Capital LP Acquires New Stake in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Buys 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
6.48%
大文字化:
|
ボリューム (24 時間):